A Phase 2 interventional study of Dostarlimab and Belrestotug. in Neoplasms, sponsored by GlaxoSmithKline. Completed at 15 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus belrestotug plus nelistotug) in participants with previously treated NSCLC.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 62 is close to the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) and
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions apply:
i) Not a woman of (WOCBP) as defined in the protocol or ii) A WOCBP who agrees to follow the protocol defined guidance during the treatment period and for at least 120 days after the last dose of study treatment.
Exclusion Criteria:
Participants who received prior treatment with the following therapies (calculation is based on date of last therapy to date of first dose of study treatment):
Prior radiation therapy: permissible if at least one non-irradiated is available for assessment per version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least 2 weeks before start of study drug for radiation of any intended use is required.
1. Greater than or equal to (>=) Grade 3 toxicity considered related to prior immunotherapy and that led to treatment discontinuation.
2. History of myocarditis of any grade during a previous treatment with immunotherapy 3. Toxicity related to prior treatment that has not resolved to \<= Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be \<= Grade 2).
History or evidence of cardiac abnormalities within the 6 months prior to enrollment which include
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dostarlimab · Drug: Belrestotug.
Drug: Dostarlimab · Drug: Belrestotug. · Drug: Nelistotug
Dostarlimab will be administered
Belrestotug will be administered
Nelistotug will be administered.
Part 1: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Arm 4)
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/ incapacity, is a congenital anomaly/ birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subset of AEs. A TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: Up to approximately 97 weeks
Part 1: Number of Participants With Any TEAEs and SAEs (Arm 5)
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/ incapacity, is a congenital anomaly/ birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subset of AEs. A TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: Up to approximately 107 weeks
Part 1: Number of Participants With Dose Limiting Toxicity (DLT) (Arm 4 and Arm 5)
A DLT is an AE meeting criteria such as, hematologic toxicities of Grade (G) 4 neutropenia/anemia/thrombocytopenia (G3 if bleeding). Non-hematological toxicities include persistent G2 eye events, colitis/diarrhea (G2 unresolved to ≤ G1 within 7 days despite immunosuppressive therapy, G3 for ≥ 72 hours, any G4), G3 pneumonitis, rash (unresolved to ≤ G2 within 2 weeks despite treatment), hypersensitivity/IRR, liver events meeting Hy's Law criteria. G3 toxicity unresolved to ≤G1 or baseline within 3 days with supportive care, or any G4 toxicity. Exclusions include G3 events of electrolyte imbalances correctable within 72 hours without effects, nausea/vomiting/fatigue resolving within 7 days, lymphopenia, and enzyme elevations without pancreatitis. Considerations for DLTs include permanent treatment discontinuation, investigator/sponsor judgment-based events including post-observation period toxicities.
Time frame: Up to 21 days
Part 1: Number of Participants Requiring Dose Modifications (Arm 4)
Number of participants with dose modifications (missed doses, dose delays and infusion interruptions) is summarized.
Time frame: Up to approximately 97 weeks
Part 1: Number of Participants Requiring Dose Modifications (Arm 5)
Number of participants with dose modifications (missed doses, dose delays and infusion interruptions) is summarized.
Time frame: Up to approximately 107 weeks
Part 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (Arm 4)
Performance Status was assessed using the ECOG scale (Grades 0-5), where 0: Fully active, able to carry on all pre-disease performance without restriction. Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of light or sedentary nature; Grade 2 - Ambulatory \& capable of all self-care but unable to carry out any work activities. Up and about more than (\>) 50% of waking hours; Grade 3 -Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; Grade 4 -Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5 -Dead.
Time frame: Up to approximately 97 weeks
Part 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (Arm 5)
Performance Status was assessed using the ECOG scale (Grades 0-5), where 0: Fully active, able to carry on all pre-disease performance without restriction. Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of light or sedentary nature; Grade 2 - Ambulatory \& capable of all self-care but unable to carry out any work activities. Up and about more than (\>) 50% of waking hours; Grade 3 -Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; Grade 4 -Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5 -Dead
Time frame: Up to approximately 107 weeks
Part 1: Number of Participants With Worst-case Post Baseline Increase From Baseline in Vital Signs (Arm 4)
Vital signs including systolic blood pressure (SBP), diastolic BP (DBP), pulse rate (PR) and body temperature (BT) were measured for the participants. DBP: Grade 0 (\<80 millimeters of mercury \[mmHg\]), Grade 1 (80-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg); SBP: Grade 0 (\<120 mmHg), Grade 1 (120-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg); PR categories include: 'Decrease to \< 60 beats per minutes \[bpm\]', 'Change to Normal' or 'No Change', and 'Increase to \>100 bpm'; BT categories include 'Decrease to \<=35 degrees Celsius °C', 'Change to Normal' or 'No Change', and 'Increase to \>=38 °C'. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Up to approximately 97 weeks
Part 1: Number of Participants With Worst-case Post Baseline Increase From Baseline in Vital Signs (Arm 5)
Vital signs including systolic blood pressure (SBP), diastolic BP (DBP), pulse rate (PR) and body temperature (BT) were measured for the participants. DBP: Grade 0 (\<80 millimeters of mercury \[mmHg\]), Grade 1 (80-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg); SBP: Grade 0 (\<120 mmHg), Grade 1 (120-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg); PR categories include: 'Decrease to \< 60 beats per minutes \[bpm\]', 'Change to Normal' or 'No Change', and 'Increase to \>100 bpm'; BT categories include 'Decrease to \<=35 degrees Celsius °C', 'Change to Normal' or 'No Change', and 'Increase to \>=38 °C'. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Up to approximately 107 weeks
Part 1: Number of Participants Who Received Concomitant Medications (Arm 4)
Number of participants who received Concomitant medications is summarized.
Time frame: Up to approximately 97 weeks
Part 1: Number of Participants Who Received Concomitant Medications (Arm 5)
Number of participants who received Concomitant medications is summarized.
Time frame: Up to approximately 107 weeks
Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline Electrocardiogram (ECG) Findings (Arm 4)
Number of participants with worst-case post baseline (WCPB) from baseline ECG findings is summarized as clinically significant. Data is summarized as Normal, Abnormal - Not Clinically Significant (NCS) and Abnormal - Clinically Significant (CS). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Up to approximately 97 weeks
Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline ECG Findings (Arm 5)
Number of participants with worst-case post baseline (WCPB) from baseline ECG findings is summarized as clinically significant. Data is summarized as Normal, Abnormal - Not Clinically Significant (NCS) and Abnormal - Clinically Significant (CS). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Up to approximately 107 weeks
Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in QTcF Interval (Arm 4)
The QTcF values based on Fridericia formula were rounded to the integer and the values are categorized into the following ranges, inclusively: Grade 0 (\<450 millisecond (msec)), Grade 1 (≥450-≤480 msec), Grade 2 (≥481-≤500 msec), and Grade 3 (≥501 msec). Missing baseline grades were assumed to be Grade 0. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Up to approximately 97 weeks
Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in QTcF Interval (Arm 5)
The QTcF values based on Fridericia formula were rounded to the integer and the values are categorized into the following ranges, inclusively: Grade 0 (\<450 millisecond (msec)), Grade 1 (≥450-≤480 msec), Grade 2 (≥481-≤500 msec), and Grade 3 (≥501 msec). Missing baseline grades were assumed to be Grade 0. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Up to approximately 107 weeks
Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in Left Ventricular Ejection Fraction (LVEF) (Arm 4)
Number of participants with worst case post-baseline in LVEF from baseline is summarized as 'any decrease (\>0%-\<10% Decrease, 10%-19% Decrease, \>=20% Decrease)', '\>=10% Decrease and \>= Lower limit of normal (LLN)', '\>=10% Decrease and \< LLN', '\>=20% Decrease and \>= LLN' and '\>=20% Decrease and \< LLN' . An increase is defined as an increase in grade relative to Baseline grade. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Up to approximately 97 weeks
Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in Left Ventricular Ejection Fraction (LVEF) (Arm 5)
Number of participants with worst case post-baseline in LVEF from baseline is summarized as 'any decrease (\>0%-\<10% Decrease, 10%-19% Decrease, \>=20% Decrease)', '\>=10% Decrease and \>= Lower limit of normal (LLN)', '\>=10% Decrease and \< LLN', '\>=20% Decrease and \>= LLN' and '\>=20% Decrease and \< LLN' . An increase is defined as an increase in grade relative to Baseline grade. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Up to approximately 107 weeks
Part 1: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 4)
Blood samples were collected for the analysis of hematology parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Up to approximately 97 weeks
Part 1: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 5)
Blood samples were collected for the analysis of hematology parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Up to approximately 107 weeks
Part 1: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 4)
Blood samples were collected for the analysis of clinical chemistry parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Up to approximately 97 weeks
Part 1: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 5)
Blood samples were collected for the analysis of clinical chemistry parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Up to approximately 107 weeks
Part 1: Number of Participants With Worst Case Change Post-baseline in Clinical Chemistry Parameters (Arm 4)
Blood samples were collected for analysis of clinical chemistry. The summaries of worst-case post baseline (WCPB) from baseline (B) with respect to normal range was analyzed. Data is presented as "XXX B YYY, WCPB YYY", where XXX denotes lab parameter and YYY is high/normal/low. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Up to approximately 97 weeks
Part 1: Number of Participants With Worst Case Change Post-baseline in Clinical Chemistry Parameters (Arm 5)
Blood samples were collected for analysis of clinical chemistry. The summaries of worst-case post baseline (WCPB) from baseline (B) with respect to normal range was analyzed. Data is presented as "XXX B YYY, WCPB YYY", where XXX denotes lab parameter and YYY is high/normal/low. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Up to approximately 107 weeks
Part 1: Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline (Arm 4)
Urinalysis was performed. Participants with missing value at baseline are assumed to be negative at baseline. All increases are from baseline. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Up to approximately 97 weeks
Part 1: Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline (Arm 5)
Urinalysis was performed. Participants with missing value at baseline are assumed to be negative at baseline. All increases are from baseline. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Up to approximately 107 weeks
Part 2: Overall Survival (OS)
OS is defined as the time from date of randomization to the date of death, irrespective of the cause of death.
Time frame: Up to approximately 107 weeks
Part 1: Objective Response Rate (ORR) (Arm 4)
ORR is defined as the percentage of participants with a best overall confirmed Complete response (CR) or Partial response (PR) at any time as per disease-specific criteria per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).
Time frame: Up to approximately 97 weeks
Part 1: Objective Response Rate (ORR) (Arm 5)
ORR is defined as the percentage of participants with a best overall confirmed CR or PR at any time as per disease-specific criteria per RECIST version 1.1. CR is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).
Time frame: Up to approximately 107 weeks
Part 1: Disease Control Rate (DCR) (Arm 4)
DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.
Time frame: Up to approximately 97 weeks
Part 1: Disease Control Rate (DCR) (Arm 5)
DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.
Time frame: Up to approximately 107 weeks
Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of Belrestotug (Arm 4)
Blood samples were collected for pharmacokinetic analysis of Belrestotug.
Time frame: Up to 21 days (Cycle 1)
Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of Belrestotug (Arm 5)
Blood samples were collected for pharmacokinetic analysis of Belrestotug.
Time frame: Up to 21 days (Cycle 1)
Part 1: Cmax and Cmin of Dostarlimab (Arm 4)
Blood samples were collected for pharmacokinetic analysis of Dostarlimab.
Time frame: Up to 21 days (Cycle 1)
Part 1: Cmax and Cmin of Dostarlimab (Arm 5)
Blood samples were collected for pharmacokinetic analysis of Dostarlimab.
Time frame: Up to 21 days (Cycle 1)
Part 1: Cmax and Cmin of Nelistotug (Arm 5)
Blood samples were collected for pharmacokinetic analysis of Nelistotug.
Time frame: Up to 21 days (Cycle 1)
Part 2: Survival Rate at 12 and 18 Months
Survival rate was planned to be anaysed at 12 and 18 months
Time frame: At 12 and 18 months
Part 2: Number of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD) and Progressive Disease (PD)
CR, PR, SD and PD was planned to be evaluated as per RECIST version 1.1 criteria. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.
Time frame: Up to approximately 107 weeks
Part 2: Progression-free Survival (PFS)
PFS is defined as time from the date of randomization to the date of disease progression as per RECIST v1.1. or death whichever occurs earlier. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.
Time frame: Up to approximately 107 weeks
Part 2: Objective Response Rate (ORR)
ORR is defined as the percentage of participants with a best overall confirmed Complete response (CR) or Partial response (PR) at any time as per disease-specific criteria per RECIST version 1.1. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).
Time frame: Up to approximately 107 weeks
Part 2: Duration of Response (DOR)
DOR is defined as the time for first documented evidence of CR or PR until disease progression or death, per RECIST 1.1 criteria. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 107 weeks
Part 2: Disease Control Rate (DCR)
DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.
Time frame: Up to approximately 107 weeks
Part 2: Number of Participants With Immune-based (i) Complete Response (iCR), Partial Response (iPR), Unconfirmed Progressive Disease (iUPD), Confirmed Progressive Disease (iCPD), and Stable Disease (iSD)
Modified RECIST 1.1 for immune-based therapeutics (iRECIST) is based on RECIST v 1.1 but adapted to account for the unique tumor response seen with immunotherapeutic drugs. iRECIST is used to assess tumor response and progression and make treatment decisions. iCR: disappearance of all target lesions; iPR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). iCPD: either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; iSD: stable disease in the absence of CR or PD and iUPD: unconfirmed progressive disease when PD is unconfirmed and NE: not evaluable.
Time frame: Up to approximately 107 weeks
Part 2: Progression-free Survival (iPFS)
iPFS is defined as time from the date of randomization to the date of disease progression or death, whichever occurs earlier, per iRECIST criteria. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.
Time frame: Up to approximately 107 weeks
Part 2: Objective Response Rate (iORR)
iORR is defined as the percentage of participants with a confirmed iCR or iPR at any time per iRECIST criteria. iCR is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 107 weeks
Part 2: Duration of Response (iDOR)
iDOR is defined as the time from first documented evidence of CR or PR until disease progression or death, per iRECIST criteria. iCR is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 107 weeks
Part 2: Number of Participants With AEs, SAEs, Adverse Events of Special Interest (AESI), AE/SAEs Leading to Dose Modifications/Delays/Withdrawals
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. AESI are considered to be Infusion Related Reactions (IRRs) and those of potential immunologic etiology. AEs were planned to be coded using the MedDRA coding system.
Time frame: Up to approximately 107 weeks
Part 2: Number of Participants With Clinically Significant Changes in Vital Signs and Laboratory Parameters
Clinically significant changes in vital signs were planned to be assessed. Blood samples were planned to be collected for the analysis of laboratory parameters.
Time frame: Up to approximately 107 weeks
Part 2: Cmax and Cmin for Dostarlimab
Blood samples were planned to be collected to assess the pharmacokinetics of Dostarlimab.
Time frame: Up to approximately 107 weeks
Part 2: Cmax and Cmin for Belrestotug
Blood samples were planned to be collected to assess the pharmacokinetics of Belrestotug.
Time frame: Up to approximately 107 weeks
Part 2: Number of Participants With Positive Anti-drug Antibodies (ADA)
Serum samples were planned to be collected for the analysis of the presence of ADAs using validated immunoassays.
Time frame: Up to approximately 107 weeks
| Milestone | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|---|---|---|
| Started | 6 | 9 | 9 | 10 | 7 | 11 | 10 |
| Dlt evaluable population | 0 | 4 | 4 | 4 | 7 | 0 | 0 |
| Completed | 6 | 6 | 7 | 8 | 7 | 9 | 9 |
| Not completed | 0 | 3 | 2 | 2 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 | 2 | 1 | 0 | 2 | 0 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/ incapacity, is a congenital anomaly/ birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subset of AEs. A TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
| Participants | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Any TEAEs | 6 | 9 | 8 |
| Any SAEs | 0 | 3 | 2 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/ incapacity, is a congenital anomaly/ birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subset of AEs. A TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
| Participants | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Any TEAEs | 10 | 6 | 11 | 9 |
| Any SAEs | 3 | 3 | 3 | 3 |
A DLT is an AE meeting criteria such as, hematologic toxicities of Grade (G) 4 neutropenia/anemia/thrombocytopenia (G3 if bleeding). Non-hematological toxicities include persistent G2 eye events, colitis/diarrhea (G2 unresolved to ≤ G1 within 7 days despite immunosuppressive therapy, G3 for ≥ 72 hours, any G4), G3 pneumonitis, rash (unresolved to ≤ G2 within 2 weeks despite treatment), hypersensitivity/IRR, liver events meeting Hy's Law criteria. G3 toxicity unresolved to ≤G1 or baseline within 3 days with supportive care, or any G4 toxicity. Exclusions include G3 events of electrolyte imbalances correctable within 72 hours without effects, nausea/vomiting/fatigue resolving within 7 days, lymphopenia, and enzyme elevations without pancreatitis. Considerations for DLTs include permanent treatment discontinuation, investigator/sponsor judgment-based events including post-observation period toxicities.
| Participants | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Part 1: Number of Participants With Dose Limiting Toxicity (DLT) (Arm 4 and Arm 5) | 0 | 0 | 0 | 1 |
Number of participants with dose modifications (missed doses, dose delays and infusion interruptions) is summarized.
| Participants | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Missed Doses | 0 | 3 | 2 |
| Dose Delays | 0 | 1 | 1 |
| Infusion Interruptions | 0 | 1 | 1 |
Number of participants with dose modifications (missed doses, dose delays and infusion interruptions) is summarized.
| Participants | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Missed Doses | 6 | 2 | 5 | 6 |
| Dose Delays | 1 | 0 | 0 | 0 |
| Infusion Interruptions | 0 | 2 | 0 | 0 |
Performance Status was assessed using the ECOG scale (Grades 0-5), where 0: Fully active, able to carry on all pre-disease performance without restriction. Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of light or sedentary nature; Grade 2 - Ambulatory \& capable of all self-care but unable to carry out any work activities. Up and about more than (\>) 50% of waking hours; Grade 3 -Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; Grade 4 -Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5 -Dead.
| Participants | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Baseline, Grade 0 | 0 | 5 | 3 |
| Baseline, Grade 1 | 6 | 4 | 6 |
| Week 4, Grade 0 | 1 | 4 | 3 |
| Week 4, Grade 1 | 3 | 3 | 4 |
| Week 4, Grade 2 | 2 | 1 | 1 |
| Week 7, Grade 0 | 1 | 2 | 1 |
| Week 7, Grade 1 | 1 | 1 | 5 |
| Week 10, Grade 0 | 1 | 2 | 1 |
| Week 10, Grade 1 | 0 | 1 | 3 |
| Week 13, Grade 0 | 1 | 1 | 1 |
| Week 13, Grade 1 | 0 | 2 | 1 |
| Week 16, Grade 0 | 1 | 1 | 1 |
| Week 16, Grade 1 | 0 | 2 | 0 |
| Week 19, Grade 0 | 1 | 0 | 1 |
| Week 19, Grade 1 | 0 | 3 | 0 |
| Week 22, Grade 0 | 1 | 0 | 0 |
| Week 22, Grade 1 | 0 | 2 | 1 |
| Week 25, Grade 0 | — | 1 | 0 |
| Week 25, Grade 1 | — | 1 | 1 |
| Week 28, Grade 0 | — | 1 | 0 |
| Week 28 Grade 1 | — | 1 | 1 |
| Week 31, Grade 0 | — | 1 | 1 |
| Week 34, Grade 0 | — | — | 1 |
| Week 37, Grade 0 | — | 1 | 1 |
| Week 40, Grade 0 | — | 1 | — |
| Week 43, Grade 0 | — | 1 | — |
| Week 46, Grade 0 | — | 1 | — |
| Week 49, Grade 0 | — | 1 | — |
| Week 52, Grade 1 | — | 1 | — |
| Week 55, Grade 1 | — | 1 | — |
| Week 58, Grade 0 | — | 1 | — |
| Week 61, Grade 0 | — | 1 | — |
| Week 64, Grade 1 | — | 1 | — |
| Week 67, Grade 1 | — | 1 | — |
| Week 70, Grade 1 | — | 1 | — |
| Treatment Discontinuation (up to 97 weeks), Grade 0 | 1 | 1 | 0 |
| Treatment Discontinuation (up to 97 weeks), Grade 1 | 2 | 5 | 4 |
| Treatment Discontinuation (up to 97 weeks), Grade 2 | 1 | 1 | 1 |
| Treatment Discontinuation (up to 97 weeks), Grade 3 | 2 | 0 | 1 |
Performance Status was assessed using the ECOG scale (Grades 0-5), where 0: Fully active, able to carry on all pre-disease performance without restriction. Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of light or sedentary nature; Grade 2 - Ambulatory \& capable of all self-care but unable to carry out any work activities. Up and about more than (\>) 50% of waking hours; Grade 3 -Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; Grade 4 -Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5 -Dead
| Participants | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Baseline, Grade 0 | 4 | 2 | 7 | 1 |
| Baseline, Grade 1 | 6 | 5 | 4 | 9 |
| Week 4, Grade 0 | 4 | 1 | 5 | 1 |
| Week 4, Grade 1 | 4 | 5 | 6 | 8 |
| Week 4, Grade 2 | 2 | 0 | 0 | 0 |
| Week 7, Grade 0 | 3 | 2 | 3 | 1 |
| Week 7, Grade 1 | 3 | 2 | 4 | 6 |
| Week 7, Grade 2 | 2 | 0 | 1 | 0 |
| Week 10, Grade 0 | 1 | 2 | 3 | 1 |
| Week 10, Grade 1 | 5 | 1 | 3 | 3 |
| Week 10, Grade 2 | 1 | 0 | 0 | 0 |
| Week 13, Grade 0 | 2 | 2 | 2 | 0 |
| Week 13, Grade 1 | 3 | 0 | 2 | 4 |
| Week 16, Grade 0 | 2 | 2 | 2 | 1 |
| Week 16, Grade 1 | 2 | 0 | 2 | 2 |
| Week 19, Grade 0 | 3 | 2 | 2 | 0 |
| Week 19, Grade 1 | 2 | 0 | 1 | 2 |
| Week 22, Grade 0 | 2 | 1 | 2 | 0 |
| Week 22, Grade 1 | 2 | 1 | 1 | 1 |
| Week 25, Grade 0 | 2 | 1 | 1 | 0 |
| Week 25, Grade 1 | 1 | 1 | 2 | 1 |
| Week 28, Grade 0 | 2 | 0 | 1 | 0 |
| Week 28, Grade 1 | 0 | 1 | 2 | 1 |
| Week 31, Grade 0 | 2 | 1 | 1 | — |
| Week 34, Grade 0 | 2 | 1 | 0 | — |
| Week 37, Grade 0 | 1 | — | 1 | — |
| Week 37, Grade 1 | 1 | — | 0 | — |
| Week 40, Grade 0 | 2 | — | 0 | — |
| Week 40, Grade 1 | 0 | — | 1 | — |
| Week 43, Grade 0 | 1 | — | 0 | — |
| Week 43, Grade 1 | 0 | — | 1 | — |
| Week 46, Grade 0 | 1 | — | 0 | — |
| Week 46, Grade 1 | 0 | — | 1 | — |
| Week 49, Grade 0 | 1 | — | 0 | — |
| Week 49, Grade 2 | 0 | — | 1 | — |
| Week 52, Grade 0 | 1 | — | — | — |
| Week 55, Grade 0 | 1 | — | — | — |
| Week 58, Grade 0 | 1 | — | — | — |
| Treatment Discontinuation (up to 107 weeks), Grade 0 | 1 | 1 | 4 | 1 |
| Treatment Discontinuation (up to 107 weeks), Grade 1 | 5 | 6 | 4 | 5 |
| Treatment Discontinuation (up to 107 weeks), Grade 2 | 1 | 0 | 1 | 1 |
| Treatment Discontinuation (up to 107 weeks), Grade 3 | 1 | 0 | 0 | 0 |
Vital signs including systolic blood pressure (SBP), diastolic BP (DBP), pulse rate (PR) and body temperature (BT) were measured for the participants. DBP: Grade 0 (\<80 millimeters of mercury \[mmHg\]), Grade 1 (80-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg); SBP: Grade 0 (\<120 mmHg), Grade 1 (120-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg); PR categories include: 'Decrease to \< 60 beats per minutes \[bpm\]', 'Change to Normal' or 'No Change', and 'Increase to \>100 bpm'; BT categories include 'Decrease to \<=35 degrees Celsius °C', 'Change to Normal' or 'No Change', and 'Increase to \>=38 °C'. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Diastolic Blood Pressure, Any Grade Increase | 0 | 2 | 2 |
| Diastolic Blood Pressure, Increase to Grade 2 | 0 | 1 | 0 |
| Diastolic Blood Pressure, Increase to Grade 3 | 0 | 0 | 1 |
| Systolic Blood Pressure, Any Grade Increase | 1 | 2 | 3 |
| Systolic Blood Pressure, Increase to Grade 2 | 1 | 2 | 2 |
| Systolic Blood Pressure, Increase to Grade 3 | 0 | 0 | 1 |
| Heart Rate, Decrease to <60 bpm | 0 | 0 | 0 |
| Heart Rate, Change to Normal or No Change | 4 | 7 | 6 |
| Heart Rate, Increase to >100 bpm | 2 | 2 | 2 |
| Temperature, Decrease to <=35 °C | 0 | 0 | 0 |
| Temperature, Change to Normal or No Change | 6 | 9 | 6 |
| Temperature, Increase to >=38 °C | 0 | 0 | 2 |
Vital signs including systolic blood pressure (SBP), diastolic BP (DBP), pulse rate (PR) and body temperature (BT) were measured for the participants. DBP: Grade 0 (\<80 millimeters of mercury \[mmHg\]), Grade 1 (80-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg); SBP: Grade 0 (\<120 mmHg), Grade 1 (120-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg); PR categories include: 'Decrease to \< 60 beats per minutes \[bpm\]', 'Change to Normal' or 'No Change', and 'Increase to \>100 bpm'; BT categories include 'Decrease to \<=35 degrees Celsius °C', 'Change to Normal' or 'No Change', and 'Increase to \>=38 °C'. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Diastolic Blood Pressure, Any Grade Increase | 5 | 1 | 4 | 5 |
| Diastolic Blood Pressure, Increase to Grade 2 | 3 | 0 | 1 | 0 |
| Diastolic Blood Pressure, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Systolic Blood Pressure, Any Grade Increase | 4 | 2 | 5 | 4 |
| Systolic Blood Pressure, Increase to Grade 2 | 1 | 1 | 2 | 1 |
| Systolic Blood Pressure, Increase to Grade 3 | 1 | 0 | 0 | 2 |
| Heart Rate, Decrease to <60 bpm | 0 | 0 | 0 | 0 |
| Heart Rate, Change to Normal or No Change | 7 | 7 | 9 | 7 |
| Heart Rate, Increase to >100 bpm | 3 | 0 | 2 | 2 |
| Temperature, Decrease to <=35 C | 0 | 0 | 0 | 0 |
| Temperature, Change to Normal or No Change | 10 | 6 | 11 | 9 |
| Temperature, Increase to >=38 C | 0 | 1 | 0 | 0 |
Number of participants who received Concomitant medications is summarized.
| Participants | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Part 1: Number of Participants Who Received Concomitant Medications (Arm 4) | 6 | 9 | 9 |
Number of participants who received Concomitant medications is summarized.
| Participants | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Part 1: Number of Participants Who Received Concomitant Medications (Arm 5) | 10 | 7 | 11 | 10 |
Number of participants with worst-case post baseline (WCPB) from baseline ECG findings is summarized as clinically significant. Data is summarized as Normal, Abnormal - Not Clinically Significant (NCS) and Abnormal - Clinically Significant (CS). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Baseline — Normal | 4 | 2 | 4 |
| Baseline — Abnormal - NCS | 2 | 6 | 3 |
| Baseline — Abnormal - CS | 0 | 0 | 2 |
| Worst-case post baseline — Normal | 2 | 2 | 3 |
| Worst-case post baseline — Abnormal - NCS | 3 | 1 | 2 |
| Worst-case post baseline — Abnormal - CS | 0 | 1 | 3 |
Number of participants with worst-case post baseline (WCPB) from baseline ECG findings is summarized as clinically significant. Data is summarized as Normal, Abnormal - Not Clinically Significant (NCS) and Abnormal - Clinically Significant (CS). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Baseline — Normal | 5 | 5 | 5 | 7 |
| Baseline — Abnormal - NCS | 4 | 1 | 5 | 2 |
| Baseline — Abnormal - CS | 1 | 1 | 1 | 1 |
| Worst-case post baseline — Normal | 0 | 5 | 4 | 4 |
| Worst-case post baseline — Abnormal - NCS | 7 | 2 | 4 | 5 |
| Worst-case post baseline — Abnormal - CS | 3 | 0 | 3 | 0 |
The QTcF values based on Fridericia formula were rounded to the integer and the values are categorized into the following ranges, inclusively: Grade 0 (\<450 millisecond (msec)), Grade 1 (≥450-≤480 msec), Grade 2 (≥481-≤500 msec), and Grade 3 (≥501 msec). Missing baseline grades were assumed to be Grade 0. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Baseline, Grade 0 | 4 | 6 | 8 |
| Baseline, Grade 1 | 1 | 0 | 0 |
| Baseline, Grade 2 | 0 | 1 | 1 |
| Baseline, Grade 3 | 1 | 1 | 0 |
| WCPB, No Grade Increase | 4 | 4 | 7 |
| WCPB, Increase to Grade 1 | 1 | 0 | 1 |
The QTcF values based on Fridericia formula were rounded to the integer and the values are categorized into the following ranges, inclusively: Grade 0 (\<450 millisecond (msec)), Grade 1 (≥450-≤480 msec), Grade 2 (≥481-≤500 msec), and Grade 3 (≥501 msec). Missing baseline grades were assumed to be Grade 0. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Baseline, Grade 0 | 10 | 6 | 10 | 9 |
| Baseline, Grade 1 | 0 | 1 | 1 | 0 |
| Baseline, Grade 2 | 0 | 0 | 0 | 0 |
| Baseline, Grade 3 | 0 | 0 | 0 | 0 |
| WCPB, No Grade Increase | 10 | 5 | 11 | 8 |
| WCPB, Increase to Grade 2 | 0 | 2 | 0 | 0 |
| WCPB, Increase to Grade 3 | 0 | 0 | 0 | 1 |
Number of participants with worst case post-baseline in LVEF from baseline is summarized as 'any decrease (\>0%-\<10% Decrease, 10%-19% Decrease, \>=20% Decrease)', '\>=10% Decrease and \>= Lower limit of normal (LLN)', '\>=10% Decrease and \< LLN', '\>=20% Decrease and \>= LLN' and '\>=20% Decrease and \< LLN' . An increase is defined as an increase in grade relative to Baseline grade. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| No change or any increase | — | 1 | — |
| Any Decrease | — | 0 | — |
| >=10% Decrease and >= LLN | — | 0 | — |
| >=10% Decrease and < LLN | — | 0 | — |
| >=20% Decrease and >= LLN | — | 0 | — |
| >=20% Decrease and < LLN | — | 0 | — |
Number of participants with worst case post-baseline in LVEF from baseline is summarized as 'any decrease (\>0%-\<10% Decrease, 10%-19% Decrease, \>=20% Decrease)', '\>=10% Decrease and \>= Lower limit of normal (LLN)', '\>=10% Decrease and \< LLN', '\>=20% Decrease and \>= LLN' and '\>=20% Decrease and \< LLN' . An increase is defined as an increase in grade relative to Baseline grade. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| No change or any increase | 2 | — | 0 | 0 |
| Any Decrease | 0 | — | 2 | 1 |
| >=10% Decrease and >= LLN | 0 | — | 0 | 0 |
| >=10% Decrease and < LLN | 0 | — | 0 | 0 |
| >=20% Decrease and >= LLN | 0 | — | 0 | 0 |
| >=20% Decrease and < LLN | 0 | — | 0 | 0 |
Blood samples were collected for the analysis of hematology parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Eosinophils, Any Grade Increase | 1 | 2 | 0 |
| Eosinophils, Increase to Grade 3 | 0 | 0 | 0 |
| Eosinophils, Increase to Grade 4 | 0 | 0 | 0 |
| Lymphocyte count decreased, Any Grade Increase | 1 | 6 | 6 |
| Lymphocyte count decreased, Increase to Grade 3 | 0 | 1 | 2 |
| Lymphocyte count decreased, Increase to Grade 4 | 0 | 0 | 0 |
| Lymphocyte count increased, Any Grade Increase | 0 | 0 | 0 |
| Lymphocyte count increased, Increase to Grade 3 | 0 | 0 | 0 |
| Lymphocyte count increased, Increase to Grade 4 | 0 | 0 | 0 |
| Platelet count decreased, Any Grade Increase | 0 | 1 | 0 |
| Platelet count decreased, Increase to Grade 3 | 0 | 0 | 0 |
| Platelet count decreased, Increase to Grade 4 | 0 | 0 | 0 |
| White blood cell decreased, Any Grade Increase | 0 | 1 | 2 |
| White blood cell decreased, Increase to Grade 3 | 0 | 0 | 0 |
| White blood cell decreased, Increase to Grade 4 | 0 | 0 | 0 |
| Anemia, Any Grade Increase | 4 | 3 | 1 |
| Anemia, Increase to Grade 3 | 0 | 1 | 0 |
| Anemia, Increase to Grade 4 | 0 | 0 | 0 |
| Hemoglobin increased, Any Grade Increase | 0 | 0 | 0 |
| Hemoglobin increased, Increase to Grade 3 | 0 | 0 | 0 |
| Hemoglobin increased, Increase to Grade 4 | 0 | 0 | 0 |
| Neutrophil count decreased, Any Grade Increase | 0 | 0 | 0 |
| Neutrophil count decreased, Increase to Grade 3 | 0 | 0 | 0 |
| Neutrophil count decreased, Increase to Grade 4 | 0 | 0 | 0 |
Blood samples were collected for the analysis of hematology parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Eosinophils, Any Grade Increase | 1 | 2 | 3 | 3 |
| Eosinophils, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Eosinophils, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased, Any Grade Increase | 8 | 4 | 8 | 8 |
| Lymphocyte count decreased, Increase to Grade 3 | 3 | 1 | 4 | 3 |
| Lymphocyte count decreased, Increase to Grade 4 | 1 | 0 | 1 | 0 |
| Lymphocyte count increased, Any Grade Increase | 0 | 0 | 0 | 0 |
| Lymphocyte count increased, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Platelet count decreased, Any Grade Increase | 1 | 0 | 2 | 0 |
| Platelet count decreased, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Platelet count decreased, Increase to Grade 4 | 0 | 0 | 1 | 0 |
| White blood cell decreased, Any Grade Increase | 0 | 1 | 0 | 1 |
| White blood cell decreased, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| White blood cell decreased, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Anemia, Any Grade Increase | 6 | 2 | 4 | 4 |
| Anemia, Increase to Grade 3 | 1 | 0 | 1 | 0 |
| Anemia, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Hemoglobin increased, Any Grade Increase | 2 | 0 | 0 | 0 |
| Hemoglobin increased, Increase to Grade 3 | 2 | 0 | 0 | 0 |
| Hemoglobin increased, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Neutrophil count decreased, Any Grade Increase | 0 | 1 | 1 | 0 |
| Neutrophil count decreased, Increase to Grade 3 | 0 | 0 | 1 | 0 |
| Neutrophil count decreased, Increase to Grade 4 | 0 | 0 | 0 | 0 |
Blood samples were collected for the analysis of clinical chemistry parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Activated Partial Thromboplastin Time (aPTT), Any Grade Increase | 0 | 0 | 0 |
| aPTT, Increase to Grade 3 | 0 | 0 | 0 |
| aPTT, Increase to Grade 4 | 0 | 0 | 0 |
| Glucose, Any Grade Increase | 0 | 2 | 0 |
| Glucose, Increase to Grade 3 | 0 | 0 | 0 |
| Glucose, Increase to Grade 4 | 0 | 0 | 0 |
| International normalized ratio (INR) increased, Any Grade Increase | 0 | 0 | 0 |
| INR increased, Increase to Grade 3 | 0 | 0 | 0 |
| INR increased, Increase to Grade 4 | 0 | 0 | 0 |
| Alkaline phosphatase (AP), Any Grade Increase | 1 | 3 | 1 |
| AP, Increase to Grade 3 | 0 | 0 | 0 |
| AP, Increase to Grade 4 | 0 | 0 | 0 |
| Alanine aminotransferase (ALT), Any Grade Increase | 1 | 2 | 0 |
| ALT, Increase to Grade 3 | 0 | 0 | 0 |
| ALT, Increase to Grade 4 | 0 | 0 | 0 |
| Aspartate aminotransferase (AST), Any Grade Increase | 1 | 1 | 0 |
| AST, Increase to Grade 3 | 0 | 0 | 0 |
| AST, Increase to Grade 4 | 0 | 0 | 0 |
| Bilirubin, Any Grade Increase | 0 | 1 | 0 |
| Bilirubin, Increase to Grade 3 | 0 | 0 | 0 |
| Bilirubin, Increase to Grade 4 | 0 | 0 | 0 |
| Creatinine, Any Grade Increase | 2 | 3 | 3 |
| Creatinine, Increase to Grade 3 | 0 | 0 | 0 |
| Creatinine, Increase to Grade 4 | 0 | 0 | 0 |
| Potassium, Any Grade Increase | 0 | 2 | 1 |
| Potassium, Increase to Grade 3 | 0 | 0 | 0 |
| Potassium, Increase to Grade 4 | 0 | 0 | 0 |
| Lactate Dehydrogenase, Any Grade Increase | 1 | 2 | 3 |
| Lactate Dehydrogenase, Increase to Grade 3 | 0 | 0 | 0 |
| Lactate Dehydrogenase, Increase to Grade 4 | 0 | 0 | 0 |
| Sodium, Any Grade Increase | 0 | 0 | 0 |
| Sodium, Increase to Grade 3 | 0 | 0 | 0 |
| Sodium, Increase to Grade 4 | 0 | 0 | 0 |
| Albumin, Any Grade Increase | 4 | 3 | 4 |
| Albumin, Increase to Grade 3 | 0 | 0 | 0 |
| Albumin, Increase to Grade 4 | 0 | 0 | 0 |
Blood samples were collected for the analysis of clinical chemistry parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| aPTT, Any Grade Increase | 0 | 0 | 0 | 0 |
| aPTT, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| aPTT, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Glucose, Any Grade Increase | 0 | 0 | 0 | 2 |
| Glucose, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Glucose, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| INR increased, Any Grade Increase | 0 | 0 | 0 | 0 |
| INR increased, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| INR increased, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| AP, Any Grade Increase | 3 | 1 | 1 | 2 |
| AP, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| AP, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| ALT, Any Grade Increase | 1 | 0 | 1 | 3 |
| ALT, Increase to Grade 3 | 0 | 0 | 0 | 1 |
| ALT, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| AST, Any Grade Increase | 0 | 2 | 3 | 2 |
| AST, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Bilirubin, Any Grade Increase | 2 | 0 | 2 | 0 |
| Bilirubin, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Bilirubin, Increase to Grade 4 | 0 | 0 | 1 | 0 |
| Creatinine, Any Grade Increase | 3 | 3 | 3 | 4 |
| Creatinine, Increase to Grade 3 | 1 | 0 | 0 | 1 |
| Creatinine, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Potassium, Any Grade Increase | 1 | 0 | 2 | 2 |
| Potassium, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Potassium, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Lactate Dehydrogenase, Any Grade Increase | 2 | 0 | 4 | 4 |
| Lactate Dehydrogenase, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Lactate Dehydrogenase, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Sodium, Any Grade Increase | 0 | 0 | 0 | 0 |
| Sodium, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Sodium, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Albumin, Any Grade Increase | 6 | 4 | 4 | 1 |
| Albumin, Increase to Grade 3 | 0 | 1 | 0 | 0 |
| Albumin, Increase to Grade 4 | 0 | 0 | 0 | 0 |
Blood samples were collected for analysis of clinical chemistry. The summaries of worst-case post baseline (WCPB) from baseline (B) with respect to normal range was analyzed. Data is presented as "XXX B YYY, WCPB YYY", where XXX denotes lab parameter and YYY is high/normal/low. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Calcium, B High, WCPB High | 0 | 1 | 1 |
| Calcium, B High, WCPB Normal | 0 | 0 | 0 |
| Calcium, B High, WCPB Low | 0 | 0 | 0 |
| Calcium, B Normal, WCPB High | 2 | 0 | 1 |
| Calcium, B Normal, WCPB Normal | 4 | 0 | 5 |
| Calcium, B Normal, WCPB Low | 0 | 0 | 1 |
| Calcium, B Low, WCPB High | 0 | 2 | 0 |
| Calcium, B Low, WCPB Normal | 0 | 7 | 0 |
| Calcium, B Low, WCPB Low | 0 | 0 | 0 |
| Lipase, B High, WCPB High | 0 | 0 | 0 |
| Lipase, B High, WCPB Normal | 0 | 0 | 0 |
| Lipase, B High, WCPB Low | 0 | 0 | 0 |
| Lipase, B Normal, WCPB High | 1 | 1 | 2 |
| Lipase, B Normal, WCPB Normal | 4 | 5 | 5 |
| Lipase, B Normal, WCPB Low | 0 | 0 | 0 |
| Lipase, B Low, WCPB High | 0 | 0 | 0 |
| Lipase, B Low, WCPB Normal | 0 | 1 | 0 |
| Lipase, B Low, WCPB Low | 0 | 0 | 0 |
| Amylase, B High, WCPB High | 0 | 1 | 0 |
| Amylase, B High, WCPB Normal | 0 | 0 | 0 |
| Amylase, B High, WCPB Low | 0 | 0 | 0 |
| Amylase, B Normal, WCPB High | 0 | 0 | 1 |
| Amylase, B Normal, WCPB Normal | 4 | 4 | 6 |
| Amylase, B Normal, WCPB Low | 1 | 1 | 0 |
| Amylase, B Low, WCPB High | 0 | 0 | 0 |
| Amylase, B Low, WCPB Normal | 0 | 0 | 0 |
| Amylase, B Low, WCPB Low | 0 | 0 | 0 |
| Urea, B High, WCPB High | 0 | 2 | 0 |
| Urea, B High, WCPB Normal | 0 | 0 | 0 |
| Urea, B High, WCPB Low | 0 | 0 | 0 |
| Urea, B Normal, WCPB High | 1 | 1 | 0 |
| Urea, B Normal, WCPB Normal | 1 | 1 | 5 |
| Urea, B Normal, WCPB Low | 1 | 0 | 1 |
| Urea, B Low, WCPB High | 0 | 0 | 0 |
| Urea, B Low, WCPB Normal | 1 | 0 | 0 |
| Urea, B Low, WCPB Low | 0 | 1 | 0 |
| Free Triiodothyronine (T3), B High, WCPB High | 0 | 0 | 0 |
| T3, B High, WCPB Normal | 0 | 0 | 0 |
| T3, B High, WCPB Low | 0 | 0 | 0 |
| T3, B Normal, WCPB High | 0 | 0 | 1 |
| T3, B Normal, WCPB Normal | 1 | 2 | 4 |
| T3, B Normal, WCPB Low | 1 | 2 | 1 |
| T3, B Low, WCPB High | 0 | 0 | 0 |
| T3, B Low, WCPB Normal | 0 | 0 | 0 |
| T3, B Low, WCPB Low | 0 | 0 | 0 |
| Free Thyroxine (T4), B High, WCPB High | 0 | 0 | 0 |
| T4, B High, WCPB Normal | 0 | 0 | 0 |
| T4, B High, WCPB Low | 0 | 0 | 0 |
| T4, B Normal, WCPB High | 0 | 0 | 0 |
| T4, B Normal, WCPB Normal | 4 | 6 | 5 |
| T4, B Normal, WCPB Low | 0 | 1 | 0 |
| T4, B Low, WCPB High | 0 | 0 | 1 |
| T4, B Low, WCPB Normal | 0 | 0 | 0 |
| T4, B Low, WCPB Low | 0 | 0 | 0 |
| Troponin I, B High, WCPB High | 0 | 1 | 0 |
| Troponin I, B High, WCPB Normal | 0 | 0 | 0 |
| Troponin I, B High, WCPB Low | 0 | 0 | 0 |
| Troponin I, B Normal, WCPB High | 0 | 2 | 0 |
| Troponin I, B Normal, WCPB Normal | 1 | 0 | 3 |
| Troponin I, B Normal, WCPB Low | 0 | 0 | 0 |
| Troponin I, B Low, WCPB High | 0 | 0 | 0 |
| Troponin I, B Low, WCPB Normal | 0 | 0 | 0 |
| Troponin I, B Low, WCPB Low | 0 | 0 | 0 |
| Thyrotropin, B High, WCPB High | 1 | 0 | 0 |
| Thyrotropin, B High, WCPB Normal | 0 | 0 | 0 |
| Thyrotropin, B High, WCPB Low | 0 | 0 | 0 |
| Thyrotropin, B Normal, WCPB High | 0 | 1 | 0 |
| Thyrotropin, B Normal, WCPB Normal | 3 | 4 | 2 |
| Thyrotropin, B Normal, WCPB Low | 0 | 1 | 5 |
| Thyrotropin, B Low, WCPB High | 0 | 0 | 0 |
| Thyrotropin, B Low, WCPB Normal | 1 | 0 | 0 |
| Thyrotropin, B Low, WCPB Low | 0 | 0 | 0 |
Blood samples were collected for analysis of clinical chemistry. The summaries of worst-case post baseline (WCPB) from baseline (B) with respect to normal range was analyzed. Data is presented as "XXX B YYY, WCPB YYY", where XXX denotes lab parameter and YYY is high/normal/low. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Calcium, B High, WCPB High | 0 | 0 | 0 | 0 |
| Calcium, B High, WCPB Normal | 0 | 0 | 0 | 1 |
| Calcium, B High, WCPB Low | 0 | 0 | 0 | 0 |
| Calcium, B Normal, WCPB High | 0 | 1 | 0 | 0 |
| Calcium, B Normal, WCPB Normal | 9 | 5 | 7 | 8 |
| Calcium, B Normal, WCPB Low | 1 | 1 | 3 | 1 |
| Calcium, B Low, WCPB High | 0 | 0 | 0 | 0 |
| Calcium, B Low, WCPB Normal | 0 | 0 | 1 | 0 |
| Calcium, B Low, WCPB Low | 0 | 0 | 0 | 0 |
| Lipase, B High, WCPB High | 2 | 0 | 0 | 0 |
| Lipase, B High, WCPB Normal | 0 | 0 | 0 | 0 |
| Lipase, B High, WCPB Low | 0 | 0 | 0 | 0 |
| Lipase, B Normal, WCPB High | 0 | 1 | 2 | 3 |
| Lipase, B Normal, WCPB Normal | 5 | 2 | 6 | 6 |
| Lipase, B Normal, WCPB Low | 0 | 0 | 1 | 0 |
| Lipase, B Low, WCPB High | 0 | 0 | 0 | 0 |
| Lipase, B Low, WCPB Normal | 0 | 0 | 0 | 0 |
| Lipase, B Low, WCPB Low | 0 | 0 | 1 | 0 |
| Amylase, B High, WCPB High | 1 | 1 | 1 | 1 |
| Amylase, B High, WCPB Normal | 0 | 0 | 0 | 0 |
| Amylase, B High, WCPB Low | 0 | 0 | 0 | 0 |
| Amylase, B Normal, WCPB High | 0 | 0 | 2 | 2 |
| Amylase, B Normal, WCPB Normal | 6 | 1 | 7 | 6 |
| Amylase, B Normal, WCPB Low | 0 | 0 | 0 | 0 |
| Amylase, B Low, WCPB High | 0 | 0 | 0 | 0 |
| Amylase, B Low, WCPB Normal | 0 | 1 | 0 | 0 |
| Amylase, B Low, WCPB Low | 0 | 0 | 0 | 0 |
| Urea, B High, WCPB High | 2 | 1 | 0 | 0 |
| Urea, B High, WCPB Normal | 0 | 0 | 0 | 0 |
| Urea, B High, WCPB Low | 0 | 0 | 0 | 0 |
| Urea, B Normal, WCPB High | 1 | 1 | 2 | 4 |
| Urea, B Normal, WCPB Normal | 2 | 4 | 3 | 3 |
| Urea, B Normal, WCPB Low | 1 | 0 | 1 | 1 |
| Urea, B Low, WCPB High | 0 | 0 | 0 | 0 |
| Urea, B Low, WCPB Normal | 0 | 0 | 0 | 0 |
| Urea, B Low, WCPB Low | 0 | 0 | 0 | 0 |
| Free Triiodothyronine (T3), B High, WCPB High | 0 | 0 | 1 | 0 |
| T3, B High, WCPB Normal | 0 | 0 | 0 | 0 |
| T3, B High, WCPB Low | 0 | 0 | 0 | 0 |
| T3, B Normal, WCPB High | 1 | 0 | 1 | 0 |
| T3, B Normal, WCPB Normal | 3 | 3 | 6 | 8 |
| T3, B Normal, WCPB Low | 1 | 0 | 1 | 1 |
| T3, B Low, WCPB High | 0 | 0 | 0 | 0 |
| T3, B Low, WCPB Normal | 0 | 0 | 0 | 0 |
| T3, B Low, WCPB Low | 2 | 1 | 0 | 0 |
| Free Thyroxine (T4), B High, WCPB High | 0 | 1 | 0 | 1 |
| T4, B High, WCPB Normal | 0 | 0 | 0 | 0 |
| T4, B High, WCPB Low | 0 | 0 | 0 | 0 |
| T4, B Normal, WCPB High | 0 | 0 | 1 | 0 |
| T4, B Normal, WCPB Normal | 7 | 3 | 7 | 8 |
| T4, B Normal, WCPB Low | 1 | 0 | 1 | 0 |
| T4, B Low, WCPB High | 0 | 0 | 0 | 0 |
| T4, B Low, WCPB Normal | 0 | 0 | 0 | 0 |
| T4, B Low, WCPB Low | 0 | 0 | 0 | 0 |
| Troponin I, B High, WCPB High | 0 | 0 | 0 | 0 |
| Troponin I, B High, WCPB Normal | 0 | 0 | 0 | 0 |
| Troponin I, B High, WCPB Low | 0 | 0 | 0 | 0 |
| Troponin I, B Normal, WCPB High | 0 | 0 | 1 | 0 |
| Troponin I, B Normal, WCPB Normal | 2 | 1 | 5 | 6 |
| Troponin I, B Normal, WCPB Low | 0 | 0 | 0 | 0 |
| Troponin I, B Low, WCPB High | 0 | 0 | 0 | 0 |
| Troponin I, B Low, WCPB Normal | 0 | 0 | 0 | 0 |
| Troponin I, B Low, WCPB Low | 0 | 0 | 0 | 0 |
| Thyrotropin, B High, WCPB High | 2 | 1 | 1 | 0 |
| Thyrotropin, B High, WCPB Normal | 0 | 0 | 0 | 1 |
| Thyrotropin, B High, WCPB Low | 0 | 0 | 0 | 0 |
| Thyrotropin, B Normal, WCPB High | 2 | 1 | 1 | 0 |
| Thyrotropin, B Normal, WCPB Normal | 5 | 3 | 5 | 7 |
| Thyrotropin, B Normal, WCPB Low | 0 | 0 | 2 | 1 |
| Thyrotropin, B Low, WCPB High | 0 | 0 | 0 | 0 |
| Thyrotropin, B Low, WCPB Normal | 0 | 0 | 1 | 0 |
| Thyrotropin, B Low, WCPB Low | 0 | 0 | 0 | 0 |
Urinalysis was performed. Participants with missing value at baseline are assumed to be negative at baseline. All increases are from baseline. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Participants | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Occult Blood, No Change/Decreased | 4 | 6 | 7 |
| Occult Blood, Any Increase | 1 | 1 | 1 |
| Occult Blood, Unknown | 0 | 0 | 0 |
| Protein, No Change/Decreased | 3 | 2 | 7 |
| Protein, Any Increase | 2 | 4 | 1 |
| Protein, Unknown | 0 | 1 | 0 |
Urinalysis was performed. Participants with missing value at baseline are assumed to be negative at baseline. All increases are from baseline. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Participants | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Occult Blood, No Change/Decreased | 4 | 5 | 6 | 6 |
| Occult Blood, Any Increase | 4 | 0 | 5 | 2 |
| Occult Blood, Unknown | 2 | 1 | 0 | 0 |
| Protein, No Change/Decreased | 3 | 5 | 5 | 7 |
| Protein, Any Increase | 5 | 1 | 6 | 1 |
| Protein, Unknown | 0 | 0 | 0 | 0 |
OS is defined as the time from date of randomization to the date of death, irrespective of the cause of death.
No measurements were reported for this outcome.
ORR is defined as the percentage of participants with a best overall confirmed Complete response (CR) or Partial response (PR) at any time as per disease-specific criteria per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).
| Percentage of Participants | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Part 1: Objective Response Rate (ORR) (Arm 4) | 0 (0.0 to 45.9) | 0 (0.0 to 33.6) | 0 (0.0 to 33.6) |
ORR is defined as the percentage of participants with a best overall confirmed CR or PR at any time as per disease-specific criteria per RECIST version 1.1. CR is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).
| Percentage of Participants | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Part 1: Objective Response Rate (ORR) (Arm 5) | 0 (0.0 to 30.8) | 0 (0.0 to 41.0) | 9 (0.2 to 41.3) | 0 (0.0 to 30.8) |
DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.
| Percentage of Participants | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Part 1: Disease Control Rate (DCR) (Arm 4) | 17 (0.4 to 64.1) | 22 (2.8 to 60.0) | 11 (0.3 to 48.2) |
DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.
| Percentage of Participants | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Part 1: Disease Control Rate (DCR) (Arm 5) | 40 (12.2 to 73.8) | 14 (0.4 to 57.9) | 27 (6.0 to 61.0) | 0 (0.0 to 30.8) |
Blood samples were collected for pharmacokinetic analysis of Belrestotug.
| Microgram/ millilitre (ug/mL) | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Cmax | 88.470 ± 92.2653 | 118.762 ± 46.4217 | 271.835 ± 77.5244 |
| Cmin | 9.412 ± 5.6264 | 22.091 ± 8.4224 | 44.350 ± 24.4184 |
Blood samples were collected for pharmacokinetic analysis of Belrestotug.
| ug/mL | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Cmax | 126.386 ± 21.8676 | 137.837 ± 34.5390 | 153.377 ± 33.5154 | 22.967 ± 7.0701 |
| Cmin | 19.408 ± 6.4103 | 20.752 ± 11.5836 | 153.069 ± 54.3450 | 21.693 ± 9.2699 |
Blood samples were collected for pharmacokinetic analysis of Dostarlimab.
| ug/mL | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] |
|---|---|---|---|
| Cmax | 119.400 ± 60.9173 | 124.278 ± 40.6026 | 97.433 ± 34.2035 |
| Cmin | 33.900 ± 15.3454 | 34.071 ± 8.5638 | 22.935 ± 7.9792 |
Blood samples were collected for pharmacokinetic analysis of Dostarlimab.
| ug/mL | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Cmax | 108.920 ± 32.2323 | 126.857 ± 51.0830 | 68.751 ± 43.8090 | 109.330 ± 121.1920 |
| Cmin | 29.290 ± 12.4519 | 34.550 ± 13.2960 | 34.218 ± 12.3900 | 39.013 ± 26.8319 |
Blood samples were collected for pharmacokinetic analysis of Nelistotug.
| ug/mL | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD |
|---|---|---|---|---|
| Cmax | 299.889 ± 313.2561 | 479.714 ± 219.7148 | 75.580 ± 12.4318 | 554.750 ± 140.7792 |
| Cmin | 43.689 ± 13.7240 | 88.243 ± 34.7201 | 15.070 ± 2.9601 | 123.975 ± 66.4588 |
Survival rate was planned to be anaysed at 12 and 18 months
No measurements were reported for this outcome.
CR, PR, SD and PD was planned to be evaluated as per RECIST version 1.1 criteria. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.
No measurements were reported for this outcome.
PFS is defined as time from the date of randomization to the date of disease progression as per RECIST v1.1. or death whichever occurs earlier. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.
No measurements were reported for this outcome.
ORR is defined as the percentage of participants with a best overall confirmed Complete response (CR) or Partial response (PR) at any time as per disease-specific criteria per RECIST version 1.1. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).
No measurements were reported for this outcome.
DOR is defined as the time for first documented evidence of CR or PR until disease progression or death, per RECIST 1.1 criteria. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
No measurements were reported for this outcome.
DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.
No measurements were reported for this outcome.
Modified RECIST 1.1 for immune-based therapeutics (iRECIST) is based on RECIST v 1.1 but adapted to account for the unique tumor response seen with immunotherapeutic drugs. iRECIST is used to assess tumor response and progression and make treatment decisions. iCR: disappearance of all target lesions; iPR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). iCPD: either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; iSD: stable disease in the absence of CR or PD and iUPD: unconfirmed progressive disease when PD is unconfirmed and NE: not evaluable.
No measurements were reported for this outcome.
iPFS is defined as time from the date of randomization to the date of disease progression or death, whichever occurs earlier, per iRECIST criteria. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.
No measurements were reported for this outcome.
iORR is defined as the percentage of participants with a confirmed iCR or iPR at any time per iRECIST criteria. iCR is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
No measurements were reported for this outcome.
iDOR is defined as the time from first documented evidence of CR or PR until disease progression or death, per iRECIST criteria. iCR is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
No measurements were reported for this outcome.
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. AESI are considered to be Infusion Related Reactions (IRRs) and those of potential immunologic etiology. AEs were planned to be coded using the MedDRA coding system.
No measurements were reported for this outcome.
Clinically significant changes in vital signs were planned to be assessed. Blood samples were planned to be collected for the analysis of laboratory parameters.
No measurements were reported for this outcome.
Blood samples were planned to be collected to assess the pharmacokinetics of Dostarlimab.
No measurements were reported for this outcome.
Blood samples were planned to be collected to assess the pharmacokinetics of Belrestotug.
No measurements were reported for this outcome.
Serum samples were planned to be collected for the analysis of the presence of ADAs using validated immunoassays.
No measurements were reported for this outcome.
Collected over All cause mortality, non-SAEs and SAEs were collected up to approximately 97 weeks for arm 4 and up to approximately 107 weeks for arm 5.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | 4/6 (66.7%) | 0/6 (0%) | 6/6 (100%) |
| Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | 5/9 (55.6%) | 3/9 (33.3%) | 9/9 (100%) |
| Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]) | 7/9 (77.8%) | 2/9 (22.2%) | 8/9 (88.9%) |
| Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | 7/10 (70%) | 3/10 (30%) | 10/10 (100%) |
| Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | 4/7 (57.1%) | 3/7 (42.9%) | 6/7 (85.7%) |
| Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | 7/11 (63.6%) | 3/11 (27.3%) | 11/11 (100%) |
| Arm 5 Randomized Part: Belrestotug(MD) + Dostarlimab + Nelistotug (HD) | 6/10 (60%) | 3/10 (30%) | 9/10 (90%) |
| Event | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]) | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug(MD) + Dostarlimab + Nelistotug (HD) |
|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/6 | 0/9 | 0/9 | 0/10 | 1/7 | 0/11 | 0/10 |
| DysphagiaGastrointestinal disorders | 0/6 | 0/9 | 0/9 | 0/10 | 1/7 | 0/11 | 0/10 |
| COVID-19 pneumoniaInfections and infestations | 0/6 | 0/9 | 0/9 | 0/10 | 1/7 | 0/11 | 0/10 |
| PneumoniaInfections and infestations | 0/6 | 1/9 | 0/9 | 0/10 | 1/7 | 0/11 | 0/10 |
| EpilepsyNervous system disorders | 0/6 | 0/9 | 0/9 | 0/10 | 1/7 | 0/11 | 0/10 |
| Immune-mediated myocarditisCardiac disorders | 0/6 | 1/9 | 0/9 | 0/10 | 0/7 | 0/11 | 0/10 |
| Pneumonia staphylococcalInfections and infestations | 0/6 | 0/9 | 1/9 | 0/10 | 0/7 | 0/11 | 0/10 |
| SepsisInfections and infestations | 0/6 | 1/9 | 0/9 | 0/10 | 0/7 | 1/11 | 0/10 |
| Ischaemic strokeNervous system disorders | 0/6 | 1/9 | 0/9 | 0/10 | 0/7 | 0/11 | 0/10 |
| NephrolithiasisRenal and urinary disorders | 0/6 | 0/9 | 1/9 | 0/10 | 0/7 | 0/11 | 0/10 |
| Event | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]) | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug(MD) + Dostarlimab + Nelistotug (HD) |
|---|---|---|---|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 1/6 | 1/9 | 3/9 | 0/10 | 3/7 | 5/11 | 1/10 |
| Decreased appetiteMetabolism and nutrition disorders | 2/6 | 4/9 | 1/9 | 1/10 | 1/7 | 2/11 | 2/10 |
| VomitingGastrointestinal disorders | 2/6 | 0/9 | 0/9 | 1/10 | 0/7 | 1/11 | 0/10 |
| Oedema peripheralGeneral disorders | 0/6 | 3/9 | 1/9 | 1/10 | 0/7 | 2/11 | 1/10 |
| PruritusSkin and subcutaneous tissue disorders | 2/6 | 3/9 | 2/9 | 2/10 | 1/7 | 2/11 | 3/10 |
| RashSkin and subcutaneous tissue disorders | 2/6 | 1/9 | 1/9 | 2/10 | 2/7 | 1/11 | 1/10 |
| Chest painGeneral disorders | 0/6 | 1/9 | 0/9 | 2/10 | 0/7 | 1/11 | 3/10 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 1/9 | 0/9 | 1/10 | 2/7 | 0/11 | 1/10 |
| PyrexiaGeneral disorders | 1/6 | 2/9 | 1/9 | 0/10 | 2/7 | 0/11 | 0/10 |
| Weight decreasedInvestigations | 1/6 | 1/9 | 1/9 | 0/10 | 2/7 | 2/11 | 1/10 |
| Age, Customized(Participants) | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Total |
|---|---|---|---|---|---|---|---|---|
| 18 to >=85 years | 6 | 9 | 9 | 10 | 7 | 11 | 10 | 62 |
| Sex: Female, Male(Participants) | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 4 | 5 | 3 | 4 | 4 | 26 |
| Male | 3 | 6 | 5 | 5 | 4 | 7 | 6 | 36 |
| Race (NIH/OMB)(Participants) | Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)] | Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)] | Arm 4: Dostarlimab + Belrestotug [High Dose (HD)] | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD | Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD | Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 4 | 7 | 8 | 10 | 6 | 8 | 5 | 48 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 1 | 0 | 0 | 3 | 3 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Dec 2021 to primary completion in May 2024, 28 months.
Results were first posted in Jul 2025, 1 year 2 months after primary completion.
Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 28 months is below that.
Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nelistotug